ScreenerHero

IMMX Immix Biopharma, Inc.

NAS · US · Healthcare · Biotechnology · immixbio.com
9.490USD-1.56%Mkt Cap: 786.75M $P/E: —

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Aus…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap786.75M USD
Enterprise Value458.53M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-29.44M USD
Revenue/Share—
Last Price9.490 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.37
PEG—
EV/EBITDA-11.05
EV/Revenue—
P/S—
P/B3.01
EPS (TTM)-0.84
EPS (Forward)-0.85
52W Range
1.98060% of range14.55
52W High14.55 USD
52W Low1.980 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-31.39%
ROA-28.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.93M USD
CapEx (TTM)732.92K USD
FCF Margin—
FCF Yield-3.23%
Net Debt-231.11M USD
Net Debt/EBITDA5.57
Balance Sheet
Debt/Equity0.01
Current Ratio25.13
Quick Ratio24.95
Book Value/Sh3.20 USD
Cash/Share3.24 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.30 USD
Upside (mean)+156.1%
Target Range17.40 USD – 30.00 USD
17.40+156.1% to mean30.00
# Analysts8
Ownership
Shares Out.82.90M
Float58.27M
Insiders14.78%
Institutions68.25%
Short Interest
Short Ratio6.6d
Short % Float16.24%
Short % Out.13.45%
Shares Short9.62M
Short (prev mo.)10.36M
Technical
SMA 5011.63 (-18.4%)
SMA 2009.168 (+3.5%)
Beta0.24
S&P 52W Chg16.45%
Avg Vol (30d)1.67M
Avg Vol (10d)2.04M
Technical Indicators
RSI (14)34.1
MACD-0.5833
MACD Signal-0.2608
MACD Hist.-0.3225
BB Upper13.82 USD
BB Middle11.44 USD
BB Lower9.051 USD
BB Width41.72%
ATR (14)0.8286 USD
Vol Ratio (20d)0.76x